CBT-004已在美国完成临床2期的首位病人入组
We are proud to announce that CBT-004, a potential first-in-class drug for vascularised pinguecula, has completed the first patient-in for Phase 2 clinical trials in December 2023 in the US. Pinguecula is a round, yellowish, elevated tissue that develops on the conjunctiva adjacent to the cornea. Cumulative exposure to UV light is the main cause […]
临床试验取得显著进展：CBT-009和CBT-004
We are proud to announce that CBT-009, our novel ophthalmic formulation of atropine indicated for the treatment of juvenile myopia, has reached agreement with FDA to enter into Phase 3 clinical trial in the USA. We have submitted our application to FDA for conducting a Phase 2 clinical trial in the United States to test […]
医药使我们能更好的视觉享受生活
Imagine a world where everyone can experience the joy and beauty of clear vision. At Cloudbreak, our mission is centered around the belief that vision is not just a sense but a gateway to a more fulfilling life. We strive to empower individuals by improving their vision and reducing the burden of eye disease. Through […]
Cloudbreak: 致力于改善视力健康的临床阶段公司
Perhaps you are unfamiliar with us and unsure of what motivates us to become a mission-driven company. Today, we are excited to share our story with you. Cloudbreak is a clinical-stage biotechnology company on a mission to improve the vision quality of people worldwide. We aim to help them see life better through medicine by […]
拨康视云入选2023年中国潜在独角兽企业
On June 20th, 2023, Greatwall Strategy Consultants (GEI) released the “2023 China Potential Unicorns Research Report”. Cloudbreak Pharma is honoured to be named one of the potential unicorn companies in China. The report showed that Suzhou ranked third in the country and first in the province in terms of number of potential unicorns with […]
拨康视云与眼视觉研究中心在香港签署战略合作备忘录
On May 17th, Cloudbreak Pharma Inc. (Cloudbreak) and Centre for Eye and Vision Research Ltd. (CEVR) signed a memorandum of understanding for strategic cooperation at the Asia Summit on Global Health (ASGH) in Hong Kong. The parties intend to explore opportunities to collaborate on research in ocular science and have reached a preliminary understanding of […]
Abu Abraham, M.D.’s appointment as Chief Medical Officer
We are pleased to announce that Abu Abraham, M.D. has joined as the group’s Chief Medical Officer. Dr. Abu Abraham has over 20 years of working experience in the pharmaceuticals and medical area. He formerly served as Vice President and Global Head of Retina and Vitreous Therapeutics at Santen, where he managed a […]
New drug CBT-009 approved to conduct Phase 1/2 clinical trial in Australia
We are pleased to announce that Australia regulatory agency has approved our application to conduct Phase 1/2 trial in Australia to evaluate safety, tolerability and pharmacodynamics of CBT-009 (atropine) on healthy volunteers. Clinical trial is scheduled to start in July 2022. Myopia is a common visual disorder and has become the major cause of visual […]
Dr. Jinsong Ni awarded Shishan Technology Innovation and Entrepreneurship “Leading Talent” title
Jinsong Ni, Ph.D, founder and CEO of Cloudbreak Pharma, has been recently awarded the title of Shishan Technology Innovation and Entrepreneurship “Leading Talent” in Suzhou High-tech Zone for 2022. Dr. Ni is the founder of Cloudbreak Pharma. He leads an R&D team that is composed of R&D experts from Allergan, the Fortune 500 […]
Cloudbreak Pharma joins Ophthalmology Tech Summit 2022
We are thrilled to participate in and be an Event Sponsor of the Ophthalmology Tech Summit 2022, which will be held on June 16-17 at Balboa Bay Resort, California. 54 speakers and over 80 KOLs will gather in the event to engage with ophthalmologists, industry leaders and entrepreneurs to share the industry developments and innovations […]
